ReviewMolecular neurodegeneration2019
Application of CRISPR genetic screens to investigate neurological diseases.
Review in Molecular neurodegeneration, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Insights from pooled CRISPRi single-cell screens in K562 cells reveal gene functions, regulatory networks, and highlight opportunities and limitations.BMC genomics · 2026Article
- Genetically Modified Primate Models for Brain Disorder Research.Neuroscience bulletin · 2026Review
- Functional Genomics: Principles and Methods.Advances in experimental medicine and biology · 2026Review
- The G protein-coupled receptor GPR89A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells.The FEBS journal · 2025Article
- Advancements in CRISPR/Cas systems for disease treatment.Acta pharmaceutica Sinica. B · 2025Review
- From morphology to single-cell molecules: high-resolution 3D histology in biomedicine.Molecular cancer · 2025Review
- CRISPR-based genetic screens in human pluripotent stem cells derived neurons and brain organoids.Cell and tissue research · 2025Review
- Death-seq identifies regulators of cell death and senolytic therapies.Cell metabolism · 2023Article
- Genetically engineered cellular models of prion propagation.Cell and tissue research · 2023Review
- Massively Parallel CRISPR-Based Genetic Perturbation Screening at Single-Cell Resolution.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Recent Advances in CRISPR-Cas Technologies for Synthetic Biology.Journal of microbiology (Seoul, Korea) · 2023Review
- Towards elucidating disease-relevant states of neurons and glia by CRISPR-based functional genomics.Genome medicine · 2022Review
- Recent advances in the use of CRISPR/Cas for understanding the early development of molecular gaps in glial cells.Frontiers in cell and developmental biology · 2022Review
- Genome-Wide Mutant Screening in Yeast Reveals that the Cell Wall is a First Shield to Discriminate Light From Heavy Lanthanides.Frontiers in microbiology · 2022Article
- Discovering antiviral restriction factors and pathways using genetic screens.The Journal of general virology · 2021Review
- Article
- Multi-omic comparison of Alzheimer's variants in human ESC-derived microglia reveals convergence at APOE.The Journal of experimental medicine · 2020Article
- APOE2: protective mechanism and therapeutic implications for Alzheimer's disease.Molecular neurodegeneration · 2020Review
- Applications of Genome-Wide Screening and Systems Biology Approaches in Drug Repositioning.Cancers · 2020Review
- Applying gene-editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The adoption of CRISPR-Cas9 technology for functional genetic screens has been a transformative advance. Due to its modular nature, this technology can be customized to address a myriad of questions. To date, pooled, genome-scale studies have uncovered genes responsible for survival, proliferation, drug resistance, viral susceptibility, and many other functions. The technology has even been applied to the functional interrogation of the non-coding genome. However, applications of this technology to neurological diseases remain scarce. This shortfall motivated the assembly of a review that will hopefully help researchers moving in this direction find their footing. The emphasis here will be on design considerations and concepts underlying this methodology. We will highlight groundbreaking studies in the CRISPR-Cas9 functional genetics field and discuss strengths and limitations of this technology for neurological disease applications. Finally, we will provide practical guidance on navigating the many choices that need to be made when implementing a CRISPR-Cas9 functional genetic screen for the study of neurological diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.